公开(公告)号：US11793788B2

公开(公告)日：2023-10-24

申请号：US16440761

申请日：2019-06-13

申请人： AstraZeneca UK Limited

发明人： Robert Peter Prybolsky ,  Judy Firor

IPC分类号： A61K31/403 ,  G16H70/40 ,  G16H10/20 ,  A61P3/10 ,  G06F16/9038 ,  G06F16/9035 ,  A61K31/513 ,  A61K31/522 ,  G06F9/54

CPC分类号： A61K31/403 ,  A61K31/513 ,  A61K31/522 ,  A61P3/10 ,  G06F9/542 ,  G06F16/9035 ,  G06F16/9038 ,  G16H10/20 ,  G16H70/40

摘要： A method is provided for lowering blood sugar in a subject in need thereof by administering a dipeptidyl peptidase-4 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the dipeptidyl peptidase-4 inhibitor pharmaceutical composition. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes saxagliptin, sitagliptin, linagliptin, alogliptin, or a pharmaceutically acceptable salt thereof. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230242626A1

公开(公告)日：2023-08-03

申请号：US18052840

申请日：2022-11-04

申请人： AstraZeneca UK Limited

发明人： Albert SCHMELZER ,  Sajal PATEL ,  Annette MEDINA ,  Austin GALLEGOS

IPC分类号： C07K16/10 ,  A61P31/14

CPC分类号： C07K16/10 ,  A61P31/14 ,  C07K2317/565

摘要： The present disclosure provides pharmaceutical compositions comprising antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.

公开(公告)号：US20230046548A1

公开(公告)日：2023-02-16

申请号：US17862342

申请日：2022-07-11

申请人： AstraZeneca UK Limited

发明人： Richard L. Skelly ,  Judy Firor

IPC分类号： G16H10/20 ,  G16H10/40 ,  G16H10/60 ,  G16H70/40 ,  G16H20/10

摘要： A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11501857B2

公开(公告)日：2022-11-15

申请号：US16440787

申请日：2019-06-13

申请人： AstraZeneca UK Limited

发明人： Robert Peter Prybolsky ,  Judy Firor

IPC分类号： G16H10/40 ,  G16H50/30 ,  G16H20/10

摘要： A method is provided for lowering blood sugar in a subject in need thereof by administering a biguanide anti-hyperglycemic pharmaceutical composition to a subject qualified for over-the-counter access to the biguanide anti-hyperglycemic pharmaceutical composition. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes N,N-dimethylimidodicarbonimidic diamide, or a pharmaceutically acceptable salt thereof. In some embodiments, the biguanide anti-hyperglycemic pharmaceutical composition includes metformin hydrochloride.

公开(公告)号：US20220184156A1

公开(公告)日：2022-06-16

申请号：US17547323

申请日：2021-12-10

申请人： ASTRAZENECA UK LIMITED

发明人： JINLIN JIANG ,  NICOLE BLECKWENN ,  RAGHAVAN VENKAT ,  DANIEL PAPPAS ,  BENJAMIN RUSH ,  GEORGE CHACKO

IPC分类号： A61K35/761 ,  C12N7/00 ,  A61K39/235

摘要： Methods for the production of adenoviruses which are suitable for use in a vaccine, and methods for increasing the yield of adenoviruses during production. These methods include adding an adenovirus to a cell population in culture; culturing the cell population under conditions which are permissive for infection of the cell population with the adenovirus to provide a cell population comprising adenovirus-infected cells; culturing the cell population comprising adenovirus-infected cells under conditions which are permissive for replication of the adenovirus; and harvesting the adenovirus from the culture.

公开(公告)号：US10028953B2

公开(公告)日：2018-07-24

申请号：US15364607

申请日：2016-11-30

申请人： AstraZeneca UK Limited

发明人： Joseph Richard Creekmore ,  Sanjeev Hukmichand Kothari ,  Bradford J. Mueller ,  Yingxu Peng

IPC分类号： A61K31/505 ,  A61K31/616 ,  A61K9/28 ,  A61K9/16 ,  A61K9/20 ,  A61K9/50 ,  A61K9/24 ,  A61K31/155 ,  A61K31/455

CPC分类号： A61K31/505 ,  A61K9/167 ,  A61K9/1676 ,  A61K9/1694 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2813 ,  A61K9/282 ,  A61K9/2866 ,  A61K9/2886 ,  A61K9/2893 ,  A61K9/501 ,  A61K9/5015 ,  A61K9/5042 ,  A61K9/5073 ,  A61K9/5078 ,  A61K31/155 ,  A61K31/455 ,  A61K31/616 ,  A61K2300/00

摘要： The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

公开(公告)号：US20180133216A1

公开(公告)日：2018-05-17

申请号：US15707376

申请日：2017-09-18

申请人： AstraZeneca UK Limited

发明人： Michael Karl Bechtold ,  Julie Kay Cahill ,  Katja Maren Fastnacht ,  Kieran James Lennon ,  Bernd Harald Liepold ,  Claudia Bettina Packhaeuser ,  Benedikt Steitz

IPC分类号： A61K31/502 ,  A61K47/20 ,  A61K47/02 ,  A61K47/12 ,  A61K9/20 ,  A61K47/32

CPC分类号： A61K31/502 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2095 ,  A61K47/02 ,  A61K47/12 ,  A61K47/20 ,  A61K47/32

摘要： The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

公开(公告)号：US09371291B2

公开(公告)日：2016-06-21

申请号：US13186363

申请日：2011-07-19

申请人： Tetsuo Okada ,  John Horbury ,  David Dermot Patrick Laffan

发明人： Tetsuo Okada ,  John Horbury ,  David Dermot Patrick Laffan

IPC分类号： C07D239/42 ,  C07D405/06

CPC分类号： C07D239/42 ,  C07D405/06 ,  Y02P20/55

摘要： A process for the manufacture of the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, useful as an HMGCoA reductase inhibitor, from a compound of the formula (7) wherein A is an acetal or ketal protecting group and R is alkyl, via isolated crystalline compounds of the formula (8) or of formula (10) is described. Crystalline intermediates of formulae 7, 8 and 10 are also described.

摘要翻译： （E）-7- [4-（4-氟苯基）-6-异丙基-2- [甲基（甲基磺酰基）氨基]嘧啶-5-基]（3R，5S）的钙盐的制备方法 由式（7）的化合物（其中A是缩醛或缩酮保护基，R是烷基）用作HMGCoA还原酶抑制剂的3,5-二羟基庚-6-烯酸经由分离的式（8）的结晶化合物 ）或式（10）。 还描述了式7,8和10的结晶中间体。

公开(公告)号：US20150152111A1

公开(公告)日：2015-06-04

申请号：US14310315

申请日：2014-06-20

申请人： AstraZeneca UK Limited

发明人： David Hardern ,  Anthony Ingall ,  Brian Springthorpe ,  Paul Willis ,  Simon Guile

IPC分类号： C07D487/04

CPC分类号： C07D487/04 ,  A61K31/519 ,  C07C211/40 ,  C07D239/48

摘要： The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.

摘要翻译： 本发明提供新的三唑并[4,5-d]嘧啶化合物，它们作为药物的用途，含有它们的组合物及其制备方法。

公开(公告)号：US20140296258A1

公开(公告)日：2014-10-02

申请号：US14068942

申请日：2013-10-31

申请人： AstraZeneca UK Limited

发明人： David Hardern ,  Anthony Ingall ,  Brian Springthorpe ,  Paul Willis ,  Simon Guile

IPC分类号： C07D487/04

CPC分类号： C07D487/04 ,  A61K31/519 ,  C07C211/40 ,  C07D239/48

摘要： The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.

摘要翻译： 本发明提供新的三唑并[4,5-d]嘧啶化合物，它们作为药物的用途，含有它们的组合物及其制备方法。